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ABSTRACT 
 
Starting with (S)-1-benzylprolinamine and α-hydroxyimino ketones, 
enantiomerically pure bisheterocyclic imidazole N-oxides bearing the (S)-configured N-
benzyl(pyrrolidin-2-yl)methyl residue were prepared. These N-oxides reacted with 
2,2,4,4-tetramethylcyclobutane-1,3-dithione to give the corresponding optically active 
imidazole-2-thione derivatives via sulfur transfer reaction. Reduction of the N-oxides 
with Raney-nickel led to deoxygenation, whereas catalytic hydrogenation (Pd/C) in 
ethanol occurred with simultaneous deoxygenation and debenzylation, leading to 
optically active 1-(pyrrolidin-2-ylmethyl)-1H-imidazoles. Alkylation of the prepared 
imidazole N-oxides and the respective imidazoles with butyl and hexylbromide and 
subsequent anion exchange gave optically active N-alkoxy- and N-alkylimidazolium 
tetrafluoroborates, respectively, with the properties of ‘room temperature ionic liquids’. 
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1. Introduction 
The importance of imidazole derivatives in organic, bioorganic, and medicinal 
chemistry as well as in materials science is well documented.2-4 In recent years, 
numerous reports on the synthesis and diverse applications of imidazole N-oxides were 
published.5 In contrast to six-membered N-heterocycles, imidazoles cannot be converted 
to the corresponding N-oxides by treatment with typical oxidizing reagents.6 Therefore, 
condensations of -hydroxyimino ketones with methylidene amines (formaldehyde 
imines) were applied as a convenient access to 2-unsubstituted imidazole N-oxides.5a,7 
Starting with optically active primary amines, such as 1-phenylethylamine, trans-
cyclohexane-1,2-diamine, as well as -amino acid esters, the desired enantiomerically 
pure imidazole N-oxides were obtained as sole products.8 Some of them were tested as 
ligands for asymmetric allylation of aldehydes9 and in cyclopropanation reactions.10 
L-Prolinamine ((2S)-pyrrolidin-2-yl)methylamine) is a very useful and widely 
applied building block for the synthesis of optically active ligands of potential 
importance for asymmetric synthesis.11 The non-protected prolinamine easily reacts 
with electron-deficient dicyanofumarates, and enantiomerically pure bicyclic 
pyrazinones were obtained chemoselectively.12 
The aim of the present study was the synthesis of new series of optically active 
imidazole derivatives containing the chiral pyrrolidine fragment originating from L-
prolinamine. Some of the products were used for the preparation of new imidazole-
based optically active ionic liquids. 
 
2. Results and discussion 
The preparation of the starting N-benzylated L-prolinamine (1) can be achieved 
from methyl L-prolinate via aminolysis and reduction of the amide13 or from L-prolinol 
via the intermediate azide.11a In addition, we developed a new approach to 1b based on 
a Mitsunobu reaction via the intermediate phthalimide derivative (Scheme 1). 
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The condensation of 1 with paraformaldehyde led to methylidene prolinamine 2, 
which spontaneously underwent trimerization to give the corresponding 
hexahydrotriazine 3 (Scheme 2). The structure of 3 was confirmed by the 13C-NMR 
spectrum, in which no signal for the imino group (N=CH2) appears. The trimerization of 
methylidene amines is a typical reaction,14 and only in the case of bulky substituents, 
e.g. adamantan-1-yl, the monomeric form is stable under standard conditions.15 In the 
case of the present study, the trimer 3 is believed to exist in solution in an equilibrium 
with the monomeric form 2. 
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Scheme 2. 
 
The latter reacts with -hydroxyimino ketones 4a-e in boiling ethanol (method 
A) or in glacial acetic acid at room temperature (method B) yielding the desired 
optically active imidazole N-oxides 5a-e in good yields (Scheme 2). In order to examine 
the enantiopurity of these products, a sample of 5a was dissolved in CDCl3 with an 
equimolar amount of (tert-butyl)(phenyl)thiophosphinic acid (MOD reagent).16 The 1H-
NMR spectrum showed only one set of signals, whereas in the case of racemic 5a (rac-
5a), addition of MOD led to the appearance of two sets. Thus, in the racemic product, 
the diagnostic H-C(2) signal of imidazole N-oxides appeared as two singlets located at 
8.87 and 8.86 ppm. Similarly, one Me group gave two singlets at 1.95 and 1.94 ppm, 
whereas the second Me group of both enantiomers absorbed as a singlet at 2.08 ppm. 
Moreover, for all other signals observed, duplication was observed in the spectrum of 
rac-5a.  
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Based on this result, we assumed that all prepared imidazole N-oxides 5 are 
enantiomerically pure. The same conclusion was formulated in the case of other 
optically active imidazole N-oxides described in our previous papers.8 
2-Unsubstituted imidazole N-oxides are versatile starting materials for the 
preparation of other imidazole derivatives, such as the parent imidazoles,8 imidazole-2-
thiones,8 imidazolones,17 and (imidazol-2-yl)acetates.18 In addition, imidazole N-oxides 
or the corresponding parent compounds have been alkylated to give imidazolium salts, 
which display properties of ionic liquids.8d,19 
Treatment of imidazole N-oxides 5 with Raney-Ni in ethanol at room temperature 
led smoothly to selective deoxygenation to yield the corresponding imidazoles 6 
(Scheme 3). Under these conditions, no debenzylation of the pyrrolidine ring was 
observed. In a control experiment, the reaction mixture was heated to reflux, and in this 
case, a complex mixture of products was formed. On the other hand, hydrogenolysis 
(H2, Pd/C) of 5c and 5d in ethanol led to deoxygenation and debenzylation to yield 7a 
and 7b, respectively. 
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Scheme 3 
 
The 2-unsubstituted imidazole N-oxides 5a,c and e reacted with 2,2,4,4-
tetramethylcyclobutane-1,3-dithione (8) via the so-called ‘sulfur-transfer reaction’ to 
give optically active imidazole-2-thiones 9a-c (Scheme 3).20 In these reactions, 
imidazole N-oxides 5 react as ‘nitrone-like’ 1,3-dipoles, and after the 1,3-dipolar 
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cycloaddition, the intermediate 1,4,2-oxathiazolidine undergoes a fragmentation to yield 
9 and 2,2,4,4-tetramethyl-3-thioxocyclobutanone. The latter can undergo the ‘sulfur-
transfer reaction’ with a molecule 5 once more, leading to 9 and 2,2,4,4-
tetramethylcyclobutane-1,3-dione. The obtained imidazole-2-thiones 9 are characterized 
by the thiourea moiety, which is of great importance in asymmetric synthesis and 
organocatalysis.21 
The alkylation of imidazoles with long-chain alkyl bromides and subsequent anion 
exchange is a typical procedure for the preparation of imidazolium salts with the 
characteristic behavior of ionic liquids (ILs).22 Optically active ionic liquids are of 
special interest, but to date, proline-derived examples are rare.23 Thus, imidazoles 6 
were alkylated with butyl, hexyl, and octyl bromide in boiling acetonitrile. The obtained 
imidazolium bromides 10 dissolved in acetone were treated with an equimolar amount 
of NaBF4 at room temperature to give the corresponding tetrafluoroborates 11 (Scheme 
4). All of them are liquids at room temperature and, therefore, belong to the class of 
optically active ‘room temperature ionic liquids’ (RTILs). 
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Scheme 4 
 
In a recent paper, we described the synthesis of a new type of ionic liquids 
containing a 3-alkoxyimidazolium cation.8d Similary, the alkylation of imidazole N-
oxides 5 were carried out with equimolar amounts of the respective alkyl bromides in 
CHCl3 solution at room temperature to give imidazolium bromides 12 (Scheme 5). The 
latter were transformed to the corresponding tetrafluoroborates 13 in the usual way. It is 
worth mentioning that under the applied reaction conditions the alkylation of 
compounds 5 and 6 occurred selectively at the imidazole fragment. 
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3. Conclusions 
The results described in the present paper show that N-benzyl L-prolinamine is a 
useful starting material for the preparation of a new type of optically active 2-
unsubstituted imidazole N-oxides. Based on the known reactivity of these N-oxides, 
they can be converted to a variety of other optically active imidazole derivatives such as 
the parent imidazoles and imidazole-2-thiones. The debenzylation with simultaneous 
deoxygenation of imidazole N-oxides 5 leading to imidazoles of type 7 can be achieved 
conveniently by hydrogenolysis under standard conditions. Alkylation of the prepared 
imidazole N-oxides as well as the corresponding imidazoles leads to N-
alkoxyimidazolium and N-alkylimidazolium salts, respectively, with the properties of 
optically active ‘room temperature ionic liquids’ (RTILs). 
The optically active products described in the present study are of interest as 
potential ligands for asymmetric synthesis and for organocatalysis. The easily available 
ionic liquids can be used as reaction media for small-scale organic synthesis. 
 
4. Experimental  
4.1. General 
 Melting points were determined in a capillary using a Melt-Temp. II apparatus 
(Aldrich) or STUART SMP30 and are uncorrected. The IR Spectra were recorded on a 
NEXUS FT-IR spectrophotometer in KBr; absorptions (ν) in cm–1. The 1H and 13C{1H} 
NMR spectra were measured on a Bruker Avance III instrument (600 and 150 MHz, 
resp.) using solvent signal as reference. Multiplicity of signals in the 13C NMR spectra 
was established using HMQC technique. Chemical shifts (´ ) are given in ppm and 
coupling constants J in Hz. Assignments of signals in 13C NMR spectra were made on 
the basis of HMQC experiments. HR-MS: Bruker maXis spectrometer; ESI-MS: Varian 
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500. Optical rotations were determined on a PERKIN-ELMER 241 MC polarimeter for 
» = 589 nm. 
 
4.2. Starting Materials  
 All solvents and reagents are commercially available and used as received. (2S)-
Benzylproline24 and ±-hydroxyimino ketones 420a were prepared according to known 
procedures.  
 
4.2.1. [(2S)-N-Benzylpyrrolidin-2-yl]methanol (N-benzylprolinol)  
 
A solution of (2S)-benzylproline (3 g, 14.6 mmol) in THF (30 ml) was cooled to 0 oC 
and a suspension of LiAlH4 in THF (2M, 21.9 mmol, 12.4 ml) was added dropwise. 
The mixture was stirred overnight at rt. Next, an aqueous solution of KOH (10%, 15 
ml) was added and the organic product was extracted with Et2O (3×15 ml). The organic 
layers were combined and dried (Na2SO4). After filtration, the solvent was evaporated 
and the crude, oily product was distilled in a Kugel-Rohr (75–78 oC, 0.1 hPa). Yield: 
2.0 g (71%). Colorless oil. IR (film): v 3405br, 2961m, 2872m, 2799m, 1879w, 1810w, 
1721w, 1496m, 1453m, 1211m, 1049w, 1029w, 849m, 839s, 699s. 1H NMR (CDCl3): 
´  7.32–7.25 (m, 5H, HC(arom.)); 3.92, 3.32 (AB, JAB = 12.9, 2H, H2C–Ph); 3.61 (dd, 
2JH,H = 10.8, 
3JH,H = 3.6, 1H, H2C–OH); 3.38 (dd, 
2JH,H = 10.8, 
3JH,H = 1.8, 1H, H2C–
OH); 2.96–2.90 (m, 1H, H2C(5)); 2.72–2.65 (m, 1H, HC(2)); 2.29–2.22 (m, 1H, 
H2C(5)); 1.93–1.85 (m, 1H, H2C(3)); 1.82–1.75 (m, 1H, H2C(3)); 1.71–1.59 (m, 2H, 
H2C(4)). 
13C NMR (CDCl3): ´  139.4 (1 C(arom.)); 128.7, 128.3, 127.1 (5 CH(arom.)); 
64.3 (C(2)); 61.8 (CH2–OH); 58.6 (CH2–Ph); 54.5 (C(5)); 27.8 (C(3)); 23.5 (C(4)). 
[±]D
25 = –58 (c = 1.0, CHCl3); lit.
25 [±]D
25 –59.9 (c = 1.0, CHCl3).  
 
4.2.2. 1-[(2S)-N-Benzylpyrrolidin-2-yl]methanamine 1  
 
To the solution of triphenylphosphine (0.86 g, 3.3 mmol) and phthalimide (0.48 g, 
3.3 mmol) in THF (10 ml), N-benzylprolinol (0.57 g, 3.0 mmol) dissolved in THF (2 
ml) was added, and the solution was stirred magnetically for 10 min. After this time, 
diethyl azodicarboxylate (DEAD) (0.62 g, 3.6 mmol) was added dropwise, and the 
mixture obtained was heated at reflux for 8 h. Next, the solvent was removed under 
reduced pressure, the obtained residue was suspended in Et2O (50 ml) and stirred for 1 
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h. Then, the precipitate was separated by filtration and the filtrate was removed under 
reduced pressure. The residue was dissolved in EtOH (20 ml), subsequently hydrazine 
monohydrate (0.4 g, 8.0 mmol) was added, the mixture was heated at reflux for 2 h, and 
after addition of HCl (1M, 3 ml) heating was continued for 30 min. The precipitate was 
filtered off and the solvents were removed under reduced pressure. The residue obtained 
was treated with aqueous NaOH (1M, 5 ml), the organic product was extracted with 
Et2O (3×25 ml), and the combined organic layers were dried (Na2SO4). After filtration, 
the Et2O solution was concentrated under reduced pressure to give 1 as a pale yellow 
oil. The crude product was distilled in a Kugel Rohr (50–52 oC, 0.1 hPa). Yield: 0.4 g 
(70%). Colorless oil. IR (film): v 3365m, 3289br, 3027m, 2961m, 2871m, 2791m, 
1950m, 1877m, 1810m, 1495s, 1453s, 1372m, 1121m, 1072m, 1028s, 910m, 738s, 
699s. 1H NMR (CDCl3): ´  7.38–7.19 (m, 5H, HC(arom.)); 3.96, 3.30 (AB, JAB = 12.9, 
2H, H2C–Ph); 2.97–2.90 (m, 1H, H2C(5)); 2.75 (dd, 
2JH,H = 12.9, 
3JH,H = 5.4, 1H, H2C–
NH2); 2.70 (dd, 
2JH,H = 12.9, 
3JH,H = 3.6, 1H, H2C–NH2); 2.58–2.53 (m, 1H, HC(2)); 
2.25–2.17 (m, 1H, H2C(5)); 1.95–1.87 (m, 1H, H2C(3)); 1.77–1.63 (m, 2H, H2C(4); 1H, 
H2C(3)). 
13C NMR (CDCl3): ´  139.9 (1 C(arom.)); 128.7, 128.7, 126.8 (5 CH(arom.)); 
65.5 (C(2)); 59.1 (CH2–Ph); 54.6 (C(5)); 44.1 (CH2–NH2); 28.0 (C(3)); 23.0 (C(4)) 
ppm. [±]D
25 = –54 (c = 1.0, CH2Cl2); lit.
26 [±]D
25 = –55 (c = 9.97, CHCl3). 
 
4.2.3. 1-[(2S)-N-Benzylpyrrolidin-2-yl]-N-methylidenemethanamine 2 resp. 3  
 
To a magnetically stirred solution of 1 (1.81 g, 9.53 mmol) in MeOH (10 ml), 
paraformaldehyde (0.30 g, 10 mmol) was added, and the mixture was stirred overnight 
at rt. Then, the solvent was removed under reduced pressure. The oil obtained was used 
in the next step without purification. Yield: 1.92 g (98%). Pale yellow oil. IR (film): v 
3361br, 3085m, 3061m, 3026m, 2960m, 2872m, 2788m, 1946m, 1875m, 1808m, 
1604m, 1495s, 1453s, 1604m, 1155w, 1028m, 916m, 735s, 698s. 1H NMR (CDCl3): ´  
7.35–7.16 (m, 5H, HC(arom.)); 4.16, 3.23 (AB, JAB = 13.2, 2H, H2C–Ph); 3.47–3.32 (br, 
2H, N–CH2–N); 2.93–2.87 (m, 1H, HC(5)); 2.68 (dd, 
2JH,H = 12.9, 
3JH,H = 4.8, 1H, 
H2C–N); 2.57–2.52 (m, 1H, HC(2)); 2.42 (dd, 
2JH,H = 12.9, 
3JH,H = 6.6, 1H, H2C–N); 
2.15–2.09 (m, 1H, HC(5)); 1.98–1.88 (m, 1H, HC(3)); 1.75–1.60 (m, 2H, H2C(4); 1H, 
H2C(3)). 
13C NMR (CDCl3): ´  139.9 (C(arom.)); 128.9, 128.2, 126.7 (5, CH(arom.)); 
75.8 (N–CH2–N); 62.4 (C(2)); 59.6 (CH2–Ph); 57.6 (CH2–N); 54.2 (C(5)); 30.2 (C(3)); 
22.6 (C(4)). ESI–MS: m/z 203 (100, [M+1]+). [±]D
25 = –14 (c = 1.0, CH2Cl2). 
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4.2.4. Synthesis of imidazole N-oxides 5 
 
Procedure A: A solution of 2 (10 mmol) and the corresponding ±-hydroxyimino 
ketone 4 (10 mmol) in EtOH (5 ml) was heated at reflux for 3 h. Next, the solvent was 
removed under reduced pressure, and the resulting residue was purified by column 
chromatography or by crystallization. 
 Procedure B: A mixture of 2 (10 mmol) and of the corresponding 4 (10 mmol) in 
glacial acetic acid (15 ml) was magnetically stirred overnight at rt. Then, HCl gas was 
bubbled through the mixture for 1 h. Next, Et2O (ca. 100 ml) was added and the 
colorless precipitated hydrochloride was filtered, washed with cold Et2O (3×20 ml), and 
dried under reduced pressure. The crude hydrochloride was dissolved in CH2Cl2 (25 
ml), solid NaHCO3 (1.5 g) was added, and stirring was continued for 1 h until evolution 
of CO2 ceased. The inorganic salts were filtered off and the solvent was removed. The 
crude products 5a-e were purified by column chromatography or by crystallization. 
 
4.2.4.1. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4,5-dimethyl-1H-imidazole 3-
oxide 5a  
Yield: 2.5 g (88%). Colorless oil (SiO2, MeOH/AcOEt, 1:1). IR (film): v 3584–
3028br, 2954m, 2926m, 2807m, 1627m, 1495m, 1453s, 1381m, 1338m, 1148m, 1041s, 
843w, 733w, 702s. 1H NMR (CDCl3): ´  7.94 (s, 1H, HC(2)); 7.35–7.21 (m, 5H, 
HC(arom.)); 3.75, 3.54 (AB, JAB = 12.6, 2H, H2C–Ph); 3.68 (dd, 
2JH,H = 14.4, 
3JH,H = 
4.8, 1H, H2C–N); 3.60 (dd, 
2JH,H = 14.4, 
3JH,H = 6.0, 1H, H2C–N); 3.04–2.99 (m, 1H, 
H2C(5’)); 2.92–2.86 (m, 1H, HC(2’)); 2.39–2.32 (m, 1H, H2C(5’)); 2.15 (s, 3H, H3C–
C(4)); 2.05 (s, 3H, H3C–C(5)); 1.93–1.85 (m, 1H, H2C(3’)); 1.75–1.69 (m, 1H, 
H2C(4’)); 1.68–1.59 (m, 1H, H2C(4’)); 1.49–1.43 (m, 1H, H2C(3’)). 
13C NMR (CDCl3): 
´  138.9 (C(arom.)); 128.8, 128.5, 127.3 (5 CH(arom.)); 126.3 (1 C(imid.)); 124.9 
(HC(2)); 121.0 (1 C(imid.)); 63.2 (HC(2’)); 60.1 (CH2–Ph); 54.8 (C(5’)); 49.1 (CH2–
N); 28.5 (C(3’)); 23.3 (C(4’)); 8.9 (CH3–C(4)); 7.3 (CH3–C(5)). HR-ESI-MS (MeOH + 
HCOOH): 286.1909 (calcd 286.1914 for C17H24N3O, [M+1]
+). [±]D
25 = –18 (c = 1.0, 
CH2Cl2). 
 
4.2.4.2. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4-methyl-5-phenyl-1H-imidazole 
3-oxide 5b  
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Yield: 1.3 g, 40% (method A), 2.7 g, 80% (method B). Colorless oil (SiO2, 
MeOH/AcOEt, 1:1). IR (film): v 3647–3028br, 2962m, 2876m, 2803m, 1683s, 1551m, 
1496s, 1452m, 1381m, 1028m, 922w, 847w, 764m, 734m, 702m, 642s. 1H NMR 
(CDCl3): ´  8.29 (s, 1H, HC(2)); 7.49–7.45 (m, 3H, HC(arom.)); 7.32–7.29 (m, 2H, 
HC(arom.)); 7.26–7.24 (m, 3H, HC(arom.)); 7.23–7.20 (m, 2H, HC(arom.)); 3.77 (dd, 
JH,H = 14.4, JH,H = 4.8, 1H, H2C–N); 3.64–3.58 (m, 1H, H2C–Ph, 1H, H2C–N); 3.38 
(AB, JAB= 12.9, 2H, H2C–Ph); 2.96–2.91 (m, 1H, H2C(5’)); 2.71–2.68 (m, 1H, 
H2C(2’)); 2.28–2.22 (m, 1H, H2C(5’)); 2.19 (s, 3H, H3C–C(4)); 1.75–1.73 (m, 1H, 
H2C(3’)); 1.63–1.60 (m, 1H, H2C(4’)); 1.53–1.48 (m, 1H, H2C(4’)); 1.33–1.29 (m, 1H, 
H2C(3’)). 
13C NMR (CDCl3): ´  138.3 (1 C(arom.)); 130.7, 129.8, 129.4, 129.1, 129.1, 
128.6, 127.5, 127.2 (9 signals for 10 CH(arom.), 2 C(arom.), 1 HC(2), 2 C(imid.)); 63.4 
(HC(2’)); 59.7 (CH2–Ph); 54.5 (C(5’)); 49.5 (CH2–N); 28.5 (C(3’)); 23.3 (C(4’)); 7.9 
(H3C–C(4)). HR-ESI-MS (MeOH + HCOOH): 348.2068 (calcd 348.2070 for 
C22H26N3O, [M+1]
+). [±]D
25 = –24 (c = 1.0, CH2Cl2). 
 
4.2.4.3. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4,5-diphenyl-1H-imidazole 3-
oxide 5c  
Yield: 2.6 g, 65% (method A), 3.1 g, 75% (method B). Colorless crystals. Mp 
160–161 oC (CHCl3/Et2O). IR (KBr): v 3646–3027br, 2961m, 2876w, 2810m, 1736m, 
1604m, 1495m, 1445m, 1346m, 1193m, 1076m, 1039s, 918m, 864s, 762s, 700s, 656m. 
1H NMR (CDCl3): ´  8.35 (s, 1H, HC(2)); 7.55–7.52 (m, 2H, HC(arom.)); 7.43–7.36 (m, 
3H, HC(arom.)); 7.32–7.28 (m, 2H, HC(arom.)); 7.27–7.19 (m, 8H, HC(arom.)); 3.75 
(dd, 2JH,H = 14.0, 
3JH,H = 4.2, 1H, H2C–N); 3.62 (dd, 
2JH,H = 14.0, 
3JH,H = 6.0, 1H, H2C–
N); 3.63, 3.39 (AB, JAB = 13.2, 2H, H2C–Ph); 2.98–2.93 (m, 1H, H2C(5’)); 2.79–2.72 
(m, 1H, HC(2’)); 2.31–2.24 (m, 1H, H2C(5’)); 1.84–1.76 (m, 1H, H2C(3’)); 1.69–1.62 
(m, 1H, H2C(4’)); 1.60–1.51 (m, 1H, H2C(4’)); 1.43–1.37 (m, 1H, H2C(3’)). 
13C NMR 
(CDCl3): ´  138.7 (1 C(arom.)); 131.0, 130.2, 129.6, 129.5, 129.1, 128.8, 128.5, 128.1, 
128.0, 127.7, 127.3, 127.3, 126.7 (2 C(arom.), 15 HC(arom.), 2 C(imid.)); 126.9 
(HC(2)) 63.1 (HC(2’)); 59.6 (CH2–Ph); 54.4 (C(5’)); 49.1 (CH2–N); 28.4 (C(4’)); 23.2 
(C(3’)). ESI HR-ESI-MS (MeOH + HCOOH): 410.2228 (calcd 410.2227 for 
C27H28N3O, [M+1]
+). [±]D
25 = –5 (c = 1.0, CH2Cl2). 
 
4.2.4.4. N-Phenyl-1-{[(2S)-N-benzylpyrrolidin-2-yl]methyl}-5-methyl-1H-
imidazole-4-carboxamide 3-oxide 5d  
 11 
Yield: 3.0 g (78%). Colorless crystals. Mp 120–122 oC (Et2O). IR (KBr): v 
3427br, 3171m, 3062m, 2978w, 2921w, 2798m, 1672s, 1619m, 1598m, 1560s, 1310s, 
1273s, 759m, 750m, 701m, 630m. 1H NMR (CDCl3): ´  12.98 (s, 1H, NH); 7.95 (s, 1H, 
HC(2)); 7.74–7.69 (m, 2H, HC(arom.)); 7.36–7.31 (m, 4H, HC(arom.)); 7.34–7.24 (m, 
4H, HC(arom.)); 3.76, 3.63 (AB, JAB = 13.6, 2H, H2C–Ph); 3.76 (dd, 
2JH,H = 14.4, 
3JH,H 
= 4.8, 1H, H2C–N); 3.66 (dd, 
2JH,H = 14.4, 
3JH,H = 5.40 Hz, 1H, H2C–N); 3.10–3.04 (m, 
1H, H2C’(5)); 3.02–2.96 (m, 1H, H2C’(2)); 2.58 (s, 3H, H3C–C(5)); 2.47–2.40 (m, 1H, 
H2C(5’)); 2.00–1.91 (m, 1H, H2C(3’)); 1.80–1.73 (m, 1H, H2C(4’)); 1.65–1.56 (m, 1H, 
H2C(4’)); 1.48–1.41 (m, 1H, H2C(3’)). 
13C NMR (CDCl3): ´  157.9 (C=O); 138.7, 138.4 
(2 C(arom.)); 131.5, 129.1, 129.0, 128.8, 127.7, 124.2, 121.7, 120.1 (10 CH(arom.), 2 
C(imid.)); 126.0 (HC(2)); 62.8 (HC(2’)); 60.3 (CH2–Ph); 55.0 (C(5’)); 48.7 (CH2–N); 
28.4 (C(3’)); 23.7 (C(4’)); 10.0 (H3C–C(5)). HR-ESI-MS (MeOH + HCOOH): 
391.2124 (calcd 391.2129 for C23H27N4O2, [M+1]
+). [±]D
25 = –27 (c = 1.0, CH2Cl2). 
 
4.2.4.5. N-(4-Bromophenyl)-1-{[(2S)-N-benzylpyrrolidin-2-yl]methyl}-5-methyl-
1H-imidazole-4-carboxamide 3-oxide 5e  
Yield: 3.8 g (81%). Colorless crystals. Mp 168–170 oC (Acetone). IR (KBr): v 
3432br, 3077m, 2975w, 2939w, 2919w, 2802m, 1675s, 1612s, 1556s, 1488s, 1309m, 
1069m, 817m, 757m, 702s, 636m, 503m. 1H NMR (CDCl3): ´  13.00 (s, 1H, NH); 7.91 
(s, 1H, HC(2)); 7.63–7.59 (m, 2H, HC(arom.)); 7.45–7.41 (m, 2H, HC(arom.)); 7.35–
7.31 (m, 2H, HC(arom.)); 7.29–7.25 (m, 3H, HC(arom.)); 3.65, 3.54 (AB, JAB = 12.6, 
2H, H2C–Ph); 3.67 (dd, 
2JH,H = 14.4, 
3JH,H = 4.8, 1H, H2C–N); 3.57 (dd, 
2JH,H = 14.4, 
3JH,H = 5.4, 1H, H2C–N); 3.09–3.03 (m, 1H, H2C(5’)); 3.02–2.95 (m, 1H, H2C(2’)); 
2.55 (s, 3H, H3C–C(5)); 2.47–2.40 (m, 1H, H2C(5’)); 2.00–1.91 (m, 1H, H2C(3’)); 
1.80–1.72 (m, 1H, H2C(4’)); 1.64–1.54 (m, 1H, H2C(4’)); 1.49–1.39 (m, 1H, H2C(3’)). 
13C NMR (CDCl3): ´  157.9 (C=O); 138.7, 137.5 (2 C(arom.)); 132.0, 131.7, 129.0, 
128.8, 127.8, 122.2, 121.5, 116.7 (1 C(arom.), 9 CH(arom.), 2 C(imid.)); 126.1 
(HC(2)); 62.8 (HC(2’)); 60.3 (CH2–Ph); 55.1 (C(5’)); 48.8 (CH2–N); 28.4 (C(3’)); 23.7 
(C(4’)); 10.0 (H3C–C(5)). HR-ESI-MS (MeOH + HCOOH): 469.1230 (calcd 469.1234 
for C23H26BrN4O2, [M(
79Br)+1]+). [±]D
25 = –22 (c = 1.0, CH2Cl2). 
 
4.2.5. Synthesis of imidazoles 6 
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To a magnetically stirred solution of an imidazole N-oxide 5 (5 mmol) in EtOH 
(15 ml), a suspension of freshly prepared Raney-Nickel in EtOH was added in small 
portions at rt. The progress of the reaction was followed by TLC (SiO2, MeOH/AcOEt 
1:1). Then, the mixture was filtered and the filtrate was concentrated under reduced 
pressure. The crude products 6a-e were purified by chromatography or by 
crystallization. 
 
4.2.5.1. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4,5-dimethyl-1H-imidazole 6a  
Yield: 1.0 g (75%). Pale yellow oil (SiO2, MeOH/AcOEt, 1:1). IR (film): v 
3428br, 2926m, 2854w, 2360w, 2342w, 1637w, 1560m, 1416m, 1245m, 1216m, 
1045w, 1021w, 801m, 748m, 700m. 1H NMR (CDCl3): ´  7.40 (s, 1H, HC(2)); 7.33–
7.29 (m, 4H, HC(arom.)); 7.26–7.21 (m, 1H, HC(arom.)); 3.76 (dd, 2JH,H = 14.4, 
3JH,H = 
4.8, 1H, H2C–N); 3.76, 3.44 (AB, JAB = 13.2, 2H, H2C–Ph); 3.66 (dd, 
2JH,H = 14.4, 
3JH,H 
= 7.2, 1H, H2C–N); 3.31–2.96 (m, 1H, H2C(5’)); 2.87–2.82 (m, 1H, H2C(2’)); 2.33–
2.27 (m, 1H, H2C(5’)); 2.13 (s, 3H, H3C–C(4)); 2.06 (s, 3H, H3C–C(5)); 1.89–1.81 (m, 
1H, H2C(3’)); 1.73–1.65 (m, 2H, H2C(4’)); 1.57–1.49 (m, 1H, H2C(3’)). 
13C NMR 
(CDCl3): ´  139.2 (1 C(arom.)); 132.0 (HC(2)); 129.8, 129.0, 126.7, 121.1, 120.2 (5 
CH(arom.); 2 C(imid.)); 63.5 (HC(2’)); 59.1 (CH2–Ph); 54.7 (C(5’)); 49.6 (CH2–N); 
29.0 (C(3’)); 23.3 (C(4’)); 8.8 (H3C–C(4)); 7.2 (H3C–C(5)) ppm. HR-ESI-MS (MeOH 
+ HCOOH): 270.1961 (calcd 270.1965 for C17H24N3, [M+1]
+). [±]D
25 = –25 (c = 1.0, 
CH2Cl2). 
 
4.2.5.2. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4-methyl-5-phenyl-1H-imidazole 
6b  
Yield: 1.2 g (70%). Pale yellow oil (SiO2, MeOH/AcOEt, 1:1). IR (film): v 3583–
3369br, 3059m, 3029m, 2948m, 2873m, 2796m, 1955m, 1888m, 1815m, 1688m, 
1605w, 1493s, 1452m, 1207m, 1124m, 1029m, 966m, 701m. 1H NMR (CDCl3): ´  7.58 
(s, 1H, HC(2)); 7.46–7.41 (m, 2H, HC(arom.)); 7.39–7.35 (m, 1H, HC(arom.)); 7.30–
7.26 (m, 4H, HC(arom.)); 7.24–7.20 (m, 1H, HC(arom.)); 7.19–7.17 (m, 2H, 
HC(arom.)); 3.92 (dd, 2JH,H = 14.4, 
3JH,H = 4.8, 1H, H2C–N); 3.76 (dd, 
2JH,H = 14.4, 
3JH,H = 7.2, 1H, H2C–N); 3.55, 3.19 (AB, JAB = 13.2, 2H, H2C–Ph; 2.89–2.85 (m, 1H, 
H2C(5’)); 2.63–2.57 (m, 1H, HC(2’)); 2.18 (s, 3H, H3C–C(4)); 2.18–2.13 (m, 1H, 
H2C(5’)); 1.73–1.65 (m, 1H, H2C(3’)); 1.62–1.50 (m, 2H, H2C(4’)); 1.40–1.34 (m, 1H, 
H2C(3’)). 
13C NMR (CDCl3): ´  139.4, 135.6 (2 C(arom.)); 136.9 (HC(2)); 130.9, 130.5, 
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129.0, 128.9, 128.5, 128.1, 127.2 (7 signals for 10 HC(arom.) + 2 C(imid.)); 63.7 
(C(2’)); 59.5 (CH2–Ph); 54.6 (C(5’)); 49.8 (CH2–N); 29.1 (C(3’)); 23.1 (C(4’)); 13.4 
(H3C–C(4)). HR-ESI-MS (MeOH + HCOOH): 332.2121 (calcd 332.2121 for C22H26N3, 
[M+1]+). [±]D
25 = –25 (c = 1.0, CH2Cl2). 
 
4.2.5.3. 4,5-Diphenyl-1-{[(2S)-N-benzylpyrrolidin-2-yl]methyl}-1H-imidazole 6c  
Yield: 1.3 g (68%). Colorless crystals. Mp 118–119 oC (CH2Cl2/hexane). IR 
(KBr): v 3432br, 3085m, 2971m, 2927m, 2905m, 2786m, 2723w, 1603m, 1505m, 
1452m, 1369m, 1256m, 774m, 698s, 653m. 1H NMR (CDCl3): ´  7.76 (s, 1H, HC(2)); 
7.54–7.45 (m, 5H, HC(arom.)); 7.39–7.36 (m, 2H, HC(arom.)); 7.33–7.28 (m, 2H, 
HC(arom.)); 7.27–7.21 (m, 5H, HC(arom.)); 7.17–7.14 (m, 1H, HC(arom.)); 3.88 (dd, 
2JH,H = 14.4, 
3JH,H = 5.4, 1H, H2C–N); 3.74 (dd, 
2JH,H = 14.4, 
3JH,H = 7.2, 1H, H2C–N); 
3.58, 3.25 (AB, JAB = 12.6, 2H, H2C–Ph); 2.96–2.91 (m, 1H, H2C(5’)); 2.72–2.66 (m, 
1H, HC(2’)); 2.26–2.19 (m, 1H, H2C(5’)); 1.83–1.76 (m, 1H, H2C(4’)); 1.70–1.58 (m, 
2H, H2C(3’)); 1.52–1.45 (m, 1H, H2C(4’)). 
13C NMR (CDCl3): ´  139.2, 138.2, 134.9 (3 
C(arom.)); 137.7 (HC(2)); 131.4, 131.3, 129.3, 129.0, 128.9, 128.7, 128.5, 128.3, 
127.2, 126.8, 126.4 (15 CH(arom.), 2 C(imid.)); 63.7 (HC(2’)); 59.6 (CH2–Ph); 54.6 
(H2C(5’)); 49.4 (CH2–N); 29.1 (C(4’)); 23.2 (C(3’)). HR-ESI-MS (MeOH + HCOOH): 
394.2278 (calcd 394.2278 for C27H28N3, [M+1]
+). [±]D
25 = –31 (c = 1.0, CH2Cl2). 
 
4.2.5.4. N-Phenyl-1-{[(2S)-N-benzylpyrrolidin-2-yl]methyl}-5-methyl-1H-
imidazole-4-carboxamide 6d  
Yield: 1.3 g (72%). Colorless crystals. Mp 82–84 oC (Et2O). IR (KBr): v 3432br, 
3270m, 3243m, 3121m, 3033m, 2969m, 2946m, 2779m, 1943w, 1968w, 1752w, 
1660s, 1596s, 1537m, 1503s, 1440s, 1246s, 878m, 759s, 697s. 1H NMR (CDCl3): ´  
9.03 (s, 1H, NH); 7.70–7.67 (m, 2H, HC(arom.)); 7.48 (s, 1H, HC(2)); 7.35–7.28 (m, 
6H, HC(arom.)); 7.27–7.24 (m, 1H, HC(arom.)); 7.09–7.07 (m, 1H, HC(arom.)); 3.81 
(dd, 2JH,H = 14.4, 
3JH,H = 4.8, 1H, H2C–N); 3.76 (dd, 
2JH,H = 14.4, 
3JH,H = 6.0, 1H, H2C–
N); 3.75, 3.49 (AB, JAB = 13.2, 2H, H2C–Ph); 3.04–2.98 (m, 1H, H2C(5’)); 2.96–2.90 
(m, 1H, HC(2’)); 2.57 (s, 3H, H3C–C(5)); 2.39–2.31 (m, 1H, H2C(5’)); 1.93–1.85 (m, 
1H, H2C(3’)); 1.75–1.69 (m, 1H, H2C(4’)); 1.67–1.58 (m, 1H, H2C(4’)); 1.54–1.46 (m, 
1H, H2C(3’)). 
13C NMR (CDCl3): ´  162.1 (C=O); 139.3, 138.7 (2 C(arom.)); 136.1 
(HC(2)); 133.2, 131.5, 129.1, 128.9, 128.7, 127.5, 123.7, 119.7 (10 HC(arom.), 2 
C(imid.)); 63.4 (HC(2’)); 60.2 (CH2–Ph); 55.0 (H2C(5’)); 49.0 (CH2–N); 29.0 (C(3’)); 
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23.4 (C(4’)); 9.9 (H3C–C(5)). HR-ESI-MS (MeOH + HCOOH): 375.2178 (calcd 
375.2179 for C23H27N4O, [M+1]
+). [±]D
25 = –11 (c = 1.0, CH2Cl2). 
 
4.2.5.5. N-(4-Bromophenyl)-1-{[(2S)-N-benzylpyrrolidin-2-yl]methyl}-5-methyl-
1H-imidazole-4-carboxamide 6e  
Yield: 2.3 g (63%). Colorless oil (SiO2, MeOH/AcOEt, 1:3). IR (film): v 3362br, 
3180s, 3061m, 3028m, 2970m, 2872m, 2799m, 1951m, 1888m, 1671m, 1588m, 
1506m, 1397m, 1241m, 1116m, 1060m, 1007s, 829s, 700m, 659m. 1H NMR (CDCl3): 
´  9.03 (s, 1H, NH); 7.69–7.57 (m, 2H, HC(arom.)); 7.48 (s, 1H, HC(2)); 7.44–7.41 (m, 
1H, HC(arom.)); 7.34–7.24 (m, 6H, HC(arom.)); 3.80–3.74 (m, 2H, H2C–N); 3.73, 3.50 
(AB, JAB = 13.2, 2H, H2C–Ph); 3.04–2.98 (m, 1H, H2C(5’)); 2.96–2.91 (m, 1H, 
HC(2’)); 2.55 (s, 3H, H3C–C(5)); 2.38–2.31 (m, 1H, H2C(5’)); 1.94–1.86 (m, 1H, 
H2C(4’)); 1.76–1.69 (m, 1H, H2C(3’)); 1.66–1.58 (m, 1H, H2C(3’)); 1.53–1.46 (m, 1H, 
H2C(4’)). 
13C NMR (CDCl3): ´  162.0 (C=O); 139.3, 137.8 (2 C(arom.)); 136.3 
(HC(2)); 132.1, 129.1, 129.0, 128.7, 127.5, 121.2, 119.7, 116.1 (1 C(arom.), 9 
CH(arom.), 2 C(imid.)); 63.4 (HC(2’)); 60.2 (CH2–Ph); 55.0 (H2C(5’)); 49.0 (CH2–N); 
29.0 (C(3’)); 23.4 (C(4’)); 9.9 (H3C–C(5)). HR-ESI-MS (MeOH + HCOOH): 453.1279 
(calcd 453.1285 for C23H26BrN4O, [M(
79Br)+1]+). [±]D
25 = –10 (c = 1.0, CH2Cl2). 
 
4.2.6. General procedure for synthesis of imidazoles 7a and 7d 
 
To a magnetically stirred solution of an imidazole N-oxide 5 (1 mmol) in MeOH (4 ml) 
10% Pd/C (0.05 g) was added and the mixture stirred under H2 atm until the reaction 
was completed (monitored by TLC). Then, the solid was filtered trough celite and the 
solvent was evaporated under reduced pressure. The obtained product was purified by 
column chromatography or by crystallization. 
 
4.2.6.1. 4,5-Diphenyl-1-[(2S)-pyrrolidin-2-ylmethyl]-1H-imidazole 7a 
Yield: 0.277 mg (87%). Colorless crystals. Mp 123–125 oC (CH2Cl2/hexane). IR 
(KBr): v 3357br, 3049m, 2989m, 2834m, 2223w, 1509m, 1439m, 1357m, 1220m, 
1033m, 907m, 895m, 802m, 731m. 1H NMR (CDCl3): ´  7.74 (s, 1H, NH); 7.48–7.43 
(m, 5H, HC(arom.)); 7.35–7.32 (m, 2H, HC(arom.)); 7.21–7.16 (m, 2H, HC(arom.)); 
7.16–7.10 (m, 1H, HC(arom.)); 3.77 (dd, 2JH,H = 12.0, 
3JH,H = 6.0, 1H, H2C–N); 3.74 
(dd, 2JH,H = 12.0, 
3JH,H = 3.6, 1H, H2C–N); 3.24–3.17 (m, 1H, HC(2’)); 2.92–2.84 (m, 
 15 
2H, H2C(5’)); 1.78–1.61 (m, 1H, H2C(3’), 2H, H2C(4’)); 1.32–1.24 (m, 1H, H2C(3’). 
13C NMR (CDCl3): ´  138.4, 137.4, 134.9, 131.3, 131.2, 129.3, 128.9, 128.6, 128.3, 
126.8, 126.4 (10 HC(arom.), 2 (C(arom.), 3 C(imid.)); 58.6 (HC(2’)); 50.5 (CH2–N); 
46.4 (H2C(5’)); 29.4 (C(4’)); 25.3 (C(3’)). HR-ESI-MS (MeOH + HCOOH): 302.1687 
(calcd 302.1685 for C17H24N3S, [M+1]
+). [±]D
25 = –18 (c = 1.0, CH2Cl2). 
 
4.2.6.2. 5-Methyl-N-phenyl-1-[(2S)-pyrrolidin-2-ylmethyl]-1H-imidazole-4-
carboxamide 7b 
Yield: 0.235 mg (83%). Colorless oil (SiO2, MeOH/AcOEt, 6:4). IR (film): v 
3366br, 3058m, 2961m, 2873m, 2246w, 1663m, 1597m, 1575m, 1442m, 1330m, 
1243m, 1064m, 906m, 877m, 829m, 756m. 1H NMR (CDCl3): ´  9.05 (s, 1H, NH); 
7.68–7.64 (m, 2H, HC(arom.)); 7.47 (s, 1H, HC(2)); 7.33–7.28 (m, 2H, HC(arom.)); 
7.08–7.03 (m, 1H, HC(arom.)); 3.86 (dd, 2JH,H = 14.1, 
3JH,H = 5.4, 1H, H2C–N); 3.78 
(dd, 2JH,H = 14.1, 
3JH,H = 7.8, 1H, H2C–N); 3.41–3.35 (m, 1H, HC(2’)); 2.94–2.89 (m, 
2H, H2C(5’)); 2.60 (s, 3H, H3C–N); 1.93–1.86 (m, 1H, H2C(3’)); 1.84–1.68 (m, 2H, 
H2C(4’)); 1.44–1.37 (m, 1H, H2C(3’)). 
13C NMR (CDCl3): ´  162.1 (C=O); 138.6 (1 
C(arom.)); 135.9, 133.1, 131.5, 129.0, 123.7, 119.7 (5 HC(arom.), 3 C(imid.)); 58.2 
(CH2–N); 50.1 (HC(2’)); 46.5 (H2C(5’)); 29.4 (C(3’)); 25.4 (C(4’)); 9.8 (CH3–N). HR-
ESI-MS (MeOH + HCOOH): 302.1687 (calcd 302.1685 for C17H24N3S, [M+1]
+). 
[±]D
25 = –24 (c = 1.0, CH2Cl2). 
 
4.2.7. Synthesis of imidazole-2-thiones 9 
 
To a magnetically stirred solution of an imidazole N-oxide 5 (4 mmol) in CHCl3 (4 ml), 
2,2,4,4-tetramethylcyclobutane-1,3-dithione 8 (2 mmol) in CHCl3 (2ml) was added 
dropwise at 0 oC, and stirring was continued overnight at rt. Then, the solvent was 
evaporated under reduced pressure and the residue was washed with hexane. The 
resulting material was purified by crystallization.  
 
4.2.7.1. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4,5-dimethyl-1,3-dihydro-2H-
imidazole-2-thione 9a  
Yield: 0.8 g (68%). Colorless crystals. Mp 108–110 oC (CH2Cl2/hexane). IR 
(KBr): v 3432br, 3085m, 2943m, 2792m, 2522w, 1659s, 1499s, 1452m, 1393m, 
1306m, 1127m, 1029m, 782m, 739s, 697s, 472s. 1H NMR (CDCl3): ´  11.45 (s, 1H, 
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NH); 7.27–7.23 (m, 4H, HC(arom.)); 7.21–7.17 (m, 1H, HC(arom.)); 4.02 (dd, 2JH,H = 
13.3, 3JH,H = 7.8, 1H, H2C–N); 3.78 (dd, 
2JH,H = 13.3, 
3JH,H = 6.0, 1H, H2C–N); 3.87, 
3.45 (AB, JAB = 13.2, 2H, H2C–Ph); 3.41–3.34 (m, 1H, HC(2’)); 2.99–2.94 (m, 1H, 
H2C(5’)); 2.28 (m, 1H, H2C(5’)); 2.03 (s, 3H, H3C–C(4)); 2.01 (s, 3H, H3C–C(5)); 
1.88–1.63 (m, 2H, H2C(4’), 2H, H2C(3’)). 
13C NMR (CDCl3): ´  158.5 (C=S); 139.2 (1 
C(arom.)); 129.0, 128.3, 127.0, 122.2, 119.9 (5 HC(arom.), 1 (C(arom.), 2 C(imid.)); 
61.9 (HC(2’)); 60.5 (CH2–Ph); 54.8 (H2C(5’)); 49.4 (CH2–N); 29.2 (C(4’)); 23.6 
(C(3’)); 9.3 (H3C–C(5)); 9.2 (H3C–C(4)). HR-ESI-MS (MeOH + HCOOH): 302.1687 
(calcd 302.1685 for C17H24N3S, [M+1]
+). [±]D
25 = –19 (c = 1.0, CH2Cl2). 
 
4.2.7.2. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4,5-diphenyl-1,3-dihydro-2H-
imidazole-2-thione 9b  
Yield: 0.5 g (31%). Colorless crystals. Mp 197–199 oC (EtOH). IR (KBr): v 
3432br, 3058m, 2937m, 2807m, 1602m, 1492s, 1397s, 1202m, 1160m, 1119m, 1073m, 
1027m, 700s, 682m, 556s. 1H NMR (CDCl3): ´  11.30 (s, 1H, NH); 7.46–7.40 (m, 3H, 
HC(arom.)); 7.36–7.33 (m, 2H, HC(arom.)); 7.25–7.16 (m, 10H, HC(arom.)); 4.12 (dd, 
2JH,H = 12.9, 
3JH,H = 9.0, 1H, H2C–N); 3.94 (dd, 
2JH,H = 12.9, 
3JH,H = 4.2, 1H, H2C–N); 
3.76, 3.22 (AB, JAB  = 12.9, 2H, H2C–Ph); 3.21–3.25 (m, 1H, HC(2’)); 2.81–2.76 (m, 
1H, H2C(5’)); 2.20–2.15 (m, 1H, H2C(5’)); 1.73–1.66 (m, 1H, H2C(4’)). 
13C NMR 
(CDCl3): ´  161.4 (C=S);  140.1 (1 C(arom.)); 131.7, 129.6, 129.3, 129.1, 129.0, 128.9, 
128.3, 128.1, 127.9, 126.9, 126.8, 125.5 (12 signals for 15 HC(arom.), 3 C(arom.), 2 
C(imid.)); 61.7 (HC(2’)); 59.9 (CH2–Ph); 54.3 (C(5’)); 49.3 (CH2–N); 29.1 (C(3’)); 
23.5 (C(4’)). HR-ESI-MS (MeOH + HCOOH): 426.1998 (calcd 426.1999 for 
C27H28N3S, [M+1]
+). [±]D
25 = –14 (c = 1.0, CH2Cl2). 
 
4.2.7.3. N-(4-Bromophenyl)-1-{[(2S)-N-benzylpyrrolidin-2-yl]methyl}-5-methyl-2-
thioxo-2,3-dihydro-1H-imidazole-4-carboxamide 9c  
Yield: 0.8 g (41%). Colorless crystals. Mp 215 oC (EtOH) (decomposition). IR 
(KBr): v 3432br, 3275m, 3125m, 3065m, 2952m, 2902w, 2787m, 1663s, 1625s, 1542s, 
1489s, 1380m, 828m, 811m, 698m, 504m. 1H NMR (CDCl3): ´  8.85 (s, 1H, HN); 
7.73–7.66 (m, 2H, HC(arom.)); 7.45–7.41 (m, 2H, HC(arom.)); 7.24–7.20 (m, 4H, 
HC(arom.)); 7.15–7.10 (m, 1H, HC(arom.)); 4.11 (dd, JH,H = 13.3, JH,H = 5.8, 1H, H2C–
N); 3.85 (dd, JH,H = 13.3, JH,H = 6.0, 1H, H2C–N); 3.74, 3.19 (AB, JAB = 12.9, 2 H, 
H2C–Ph); 3.42–3.33 (m, 1H, H2C(5’)); 3.08–3.02 (m, 1H, HC(2’)); 2.57 (s, 3H, H3C–
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C(5)); 2.46–2.35 (m, 1H, H2C(5’)); 1.92–1.85 (m, 1H, H2C(4’)); 1.83–1.68 (m, 2H, 
H2C(3’), 1H H2C(4’)). 
13C NMR (CDCl3): ´  162.1 (C=S); 161.6 (C=O); 138.7, 138.0 (2 
C(arom.)); 136.6 (HC(2)); 132.7, 129.6, 129.1, 128.9, 121.7, 119.7, 116.1 (9 
HC(arom.), 1 C(arom.)), 2 C(imid.)); 63.8 (C(2’)); 60.9 (CH2–Ph); 55.3 (C(5’)); 49.2 
(CH2–N); 29.7 (C(3’)); 23.1 (C(4’)); 10.0 (H3C–C(5)). HR-ESI-MS (MeOH + 
HCOOH): 485.1002 (calcd 485.1005 for C23H26BrN4OS, [M+1]
+). [±]D
25 = –10 (c = 
1.0, CH2Cl2). 
 
4.2.8. Synthesis of 3-alkylimidazolium tetrafluoroborates 11 
 
A solution of an imidazole 6 (5 mmol) and an alkyl bromide (5 mmol) in 
acetonitrile (5 ml) was heated at reflux for 16 h. Then, the solvent was removed under 
reduced pressure, the resulting product was washed with Et2O (3×5 ml), and dried under 
high vacuum for 4 h. The imidazolium bromide obtained was magnetically stirred with 
an equimolar amount of solid NaBF4 in acetone (5 ml) overnight at rt. The resulting 
suspension was filtered through neutral alumina (CHCl3) and the solvent evaporated 
under reduced pressure. 
 
4.2.8.1. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-3-hexyl-4,5-dimethyl-1H-
imidazolium tetrafluoroborate 11a  
Yield: 1.6 g (75%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3648w, 3628w, 
3566m, 3154m, 3087m, 2956m, 2931m, 2805m, 1818m, 1564m, 1455m, 1058br, 
742m, 703m, 626m. 1H NMR (CDCl3): ´  8.72 (HC(2)); 7.29–7.26 (m, 2H, HC(arom.)); 
7.23–7.19 (m, 3H, HC(arom.)); 4.01–3.95 (m, 1H, H2C–N, 2H, H2C(alk.)); 3.89 (dd, 
2JH,H = 13.8, 
3JH,H = 6.6, 1H, H2C–N); 3.59, 3.56 (AB, JAB = 13.2, 2H, H2C–Ph); 3.16–
3.11 (m, 1H, HC(2’)); 3.10–3.06 (m, 1H, H2C(5’)); 2.50–2.45 (m, 1H, H2C(5’)); 2.16 
(s, 3H, H3C–C(4)); 2.12 (s, 3H, H3C–C(5)); 2.05–1.98 (m, 1H, H2C(3’)); 1.83–1.77 (m, 
1H, H2C(4’)); 1.74–1.67 (m, 1H, H2C(4’); 2H, H2C(alk.)); 1.55–1.50 (m, 1H, H2C(3’)); 
1.32–1.24 (m, 6H, H2C(alk.)); 0.85 (t, JH,H = 7.2, 3H, H3C(alk.)). 
13C NMR (CDCl3): ´  
139.4 (1 C(arom.); 135.4 (HC(2)); 128.9, 128.5, 127.3, 127.2, 126.0 (5 CH(arom.), 2 
C(imid.)); 62.7 (HC(2’)); 60.5 (CH2–Ph); 54.9 (H2C(5’)); 50.8 (CH2–N); 47.4, 31.3, 
29.9 (3 C(alk.)); 28.5 (C(4’)); 26.1 (C(alk.)); 23.9 (C(3’)); 22.6 (C(alk.)); 14.1 
(H3C(alk.)); 8.7 (H3C–C(5)); 8.5 (H3C–C(4)). [±]D
25 = –35 (c = 1.0, CH2Cl2). 
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4.2.8.2. 1-{[(2S)-N-Benzylopyrrolidin-2-yl]methyl}-4,5-dimethyl-3-octyl-1H-
imidazolium tetrafluoroborate 11b  
Yield: 1.6 g (70%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3584w, 3154m, 
3087m, 2928m, 2857m, 2806m, 1733w, 1699w, 1565s, 1454m, 1202m, 1058br, 828w, 
742m, 703m. 1H NMR (CDCl3): ´  8.73 (s, 1H, HC(2)); 7.28–7.25 (m, 2H, HC(arom.)); 
7.23–7.18 (m, 3H, HC(arom.)); 3.98 (dd, 2JH,H = 14.4, 
3JH,H = 5.4, 1H, H2C–N); 3.97–
3.94 (m, 2H, H2C(alk.)); 3.88 (dd, 
2JH,H = 14.4, 
3JH,H = 7.2, 1H, H2C–N); 3.57, 3.55 
(AB, JAB = 13.6, 2H, H2C–Ph); 3.16–3.11 (m, 1H, H2C(2’)); 3.10–3.05 (m, 1H, 
H2C(5’)); 2.50–2.44 (m, 1H, H2C(5’)); 2.15 (s, 3H, H3C–C(4)); 2.10 (s, 3H, H3C–
C(5)); 1.97–1.82 (m, 1H, H2C(3’)); 1.82–1.77 (m, 1H, H2C(3’)); 1.74–1.67 (m, 1H, 
H2C(4’), 2H, H2C(alk.)); 1.55–1.49 (m, 1H, H2C(4’)); 1.31–1.21 (m, 10H, H2C(alk.)); 
8.62 (t, JH,H = 6.9, H3C(alk.)). 
13C NMR (CDCl3): ´  139.3 (1 C(arom.); 135.4 (HC(2)); 
128.9, 128.5, 127.2, 127.2, 126.0 (5 HC(arom.), 2 C(imid.)); 62.6 (HC(2’)); 60.4 (CH2–
Ph); 54.9 (C(5’)); 50.8 (CH2–N); 47.4, 31.8, 29.9, 29.2, 29.1 (5 C(alk.)); 28.4 (C(3’)); 
26.5 (C(alk.)); 23.9 (C(4’)); 22.7 (C(alk.)); 14.2 (H3C(alk.)); 8.7 (H3C–C(4)); 8.5 
(H3C–C(5)). [±]D
25 = –22 (c = 1.0, CH2Cl2). 
 
4.2.8.3. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-3-butyl-4-methyl-5-phenyl-1H-
imidazolium tetrafluoroborate 11c  
Yield: 1.6 g (68%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3151m, 3084m, 
2961m, 2874m, 2807m, 1559m, 1497m, 1453m, 1203m, 1058m, 846w, 765m, 703s. 
1H NMR (CDCl3): ´  8.91 (s, 1H, HC(2)); 7.55–7.50 (m, 3H, HC(arom.)); 7.29–7.26 
(m, 4H, HC(arom.)); 7.24–7.21 (m, 1H, HC(arom.)); 7.17–7.15 (m, 2H, HC(arom.)); 
4.09–4.07 (m, 2H, H2C(alk.)); 3.97 (dd, 
2JH,H = 14.0, 
3JH,H = 5.4, 1H, H2C–N); 3.93 
(dd, 2JH,H = 14.0, 
3JH,H = 6.6, 1H, H2C–N); 3.52, 3.43 (AB, JAB = 13.2, 2H, H2C–Ph); 
3.00–2.96 (m, 1H, H2C(5’)); 2.93–2.88 (m, 1H, H2C(2’)); 2.43–2.37 (m, 1H, H2C(5’)); 
2.16 (s, 3H, H3C–C(4)); 1.86–1.76 (m, 1H, H2C(3’), 2H, H2C(alk.)); 1.74–1.66 (m, 1H, 
H2C(4’)); 1.60–1.53 (m, 1H, H2C(4’)); 1.44–1.38 (m, 2H, H2C(alk.)); 1.36–1.31 (m, 
1H, H2C(3’)); 0.97 (t, JH,H = 7.50 Hz, H3C(alk.)). 
13C NMR (CDCl3): ´  139.3 (1 
C(arom.)); 136.2 (HC(2)), 131.7, 130.9, 130.7, 129.7, 128.9, 128.5, 127.5, 127.3, 125.6 
(10 HC(arom.), 1 C(arom.), 2 C(imid.)); 62.6 (HC(2’)); 59.9 (CH2–Ph); 54.4 (H2C(5’)); 
50.9 (CH2–N); 47.6, 31.8 (2 C(alk.)); 28.4 (C(3’)); 23.7 (C(4’)); 19.8 (C(alk.)); 13.6 
(H3C(alk.)); 8.9 (H3C–C(4)). [±]D
25 = –10 (c = 1.0, CH2Cl2). 
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4.2.8.4. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4-methyl-3-octyl-5-phenyl-1H-
imidazolium tetrafluoroborate 11d  
Yield: 1.9 g (72%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3627w, 3557w, 
3151m, 3062m, 2927m, 2857m, 2804m, 1966m, 1900m, 1822m, 1559m, 1496m, 
1459m, 1208m, 1058m, 926m, 843m, 763s, 703m. 1H NMR (CDCl3): ´  9.00 (s, 1H, 
HC(2)); 7.55–7.50 (m, 3H, HC(arom.)); 7.29–7.26 (m, 4H, HC(arom.)); 7.24–7.21 (m, 
1H, HC(arom.)); 7.18–7.16 (m, 2H, HC(arom.)); 3.99 (dd, 2JH,H = 14.0, 
3JH,H = 5.4, 1H, 
H2C–N); 3.94 (dd, 
2JH,H = 14.0, 
3JH,H = 6.6, 1H, H2C–N); 3.54, 3.43 (AB, JAB = 13.2, 
2H, H2C–Ph); 3.00–2.96 (m, 1H, H2C(5’)); 2.94–2.90 (m, 1H, HC(2’)); 2.42–2.37 (m, 
1H, H2C(5’)); 2.16 (s, 3H, H3C–C(5)); 1.87–1.77 (m, 2H, H2C(alk.), 1H, H2C(4’)); 
1.73–1.67 (m, 1H, H2C(3’)); 1.60–1.52 (m, 1H, H2C(3’)); 1.39–1.21 (m, 10H, 
H2C(alk.), 1H, H2C(4’)); 0.87 (t, JH,H = 7.2, H3C(alk.)). 
13C NMR (CDCl3): ´  139.3 (1 
C(arom.); 136.2 (HC(2)); 131.7, 130.8, 130.7, 129.6, 128.9, 128.5, 127.5, 127.2, 125.5 
(10 HC(arom.), 2 C(arom.) 2 C(imid.)); 62.6 (C(2’)); 59.9 (CH2–Ph); 54.4 (H2C(5’)); 
50.8 (CH2-N); 47.8, 31.9, 29.9, 29.2 (4 C(alk.)); 29.2 (C(3’)); 28.3, 26.6 (2 C(alk.)); 
23.7 (C(4’)); 22.8 (C(alk.)); 14.2 (H3C(alk.)); 8.9 (H3C–C(5)). [±]D
25 = –27 (c = 1.0, 
CH2Cl2). 
 
4.2.9. Synthesis of 3-alkoxyimidazolium tetrafluoroborates 13 
 
A solution of an imidazole N-oxide 5 (5 mmol) and the corresponding alkyl bromide (5 
mmol) in CHCl3 (10 ml) was magnetically stirred at rt for 72 h. Then, the solvent was 
removed under reduced pressure and the crude product was washed with Et2O (3×5 ml), 
and dried under high vacuum for 4 h. The imidazolium bromide obtained was 
magnetically stirred with an equimolar amount of solid NaBF4 in acetone (5 ml) at rt 
overnight. The resulting suspension was filtered through neutral alumina (Et2O) and the 
solvent evaporated under reduced pressure. 
 
4.2.9.1. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-3-butoxy-4,5-dimethyl-1H-
imidazolium tetrafluoroborate 13a  
Yield: 1.8 g (78%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3585w, 3380m, 
3140m, 2961m, 2874m, 2807m, 1684m, 1545m, 1496m, 1454m, 1259w, 1187w, 
1058m, 936m, 848m, 820m, 735s, 703s, 613w. 1H NMR (CDCl3): ´  9.28 (s, 1H, 
HC(2)); 7.31–7.14 (m, 5H, HC(arom.)); 4.38–4.29 (m, 2H, H2C(alk.)); 4.09 (dd, 
2JH,H = 
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14.4, 3JH,H = 4.8, 1H, H2C–N); 3.96 (dd, 
2JH,H = 14.4, 
3JH,H = 7.8, 1H, H2C–N); 3.59, 
3.56 (AB, JAB = 13.2, 1H, H2C–Ph); 3.19–3.11 (m, 1H, H2C(5’), 1H, HC(2’)); 2.57–
2.52 (m, 1H, H2C(5’)); 2.15 (s, 3H, H3C–C(4)); 2.08 (s, 3H, H3C–C(5)); 2.06–2.00 (m, 
1H, H2C(3’)); 1.86–1.79 (m, 1H, H2C(4’)); 1.79–1.71 (m, 2H, H2C(alk.), 1H, H2C(4’)); 
1.56–1.44 (m, 2H, H2C(alk.); 1H, H2C(3’)); 0.97 (t, JH,H = 7.2, H3C(alk.)). 
13C NMR 
(CDCl3): ´  139.2 (1 C(arom.)); 131.7 (HC(2)); 129.0, 128.5, 127.3, 124.8, 123.5 (5 
CH(arom.), 2 C(imid.)); 82.9 (C(alk.)); 62.5 (C(2’)); 60.6 (CH2–Ph); 55.0 (C(5’)); 50.9 
(CH2–N); 29.9 (C(alk.)); 28.3 (C(3’)); 24.0 (C(4’)); 19.0 (C(alk.)); 13.9 (H3C(alk.)); 
8.7 (H3C-C(5)); 7.2 (H3C–C(4)). [±]D
25 = –33 (c = 1.0, CH2Cl2). 
 
4.2.9.2. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-4,5-dimethyl-3-octyloxy-1H-
imidazolium tetrafluoroborate 13b  
Yield: 1.7 g (69%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3584w, 3566w, 
3384m, 3139m, 3061m, 2928m, 2857m, 2807m, 1634m, 1546m, 1496w, 1454w, 
1260w, 1059m, 945m, 807w, 736m, 703s, 648w. 1H NMR (CDCl3): ´  8.91 (s, 1H, 
HC(2)); 7.27–7.19 (m, 3H, HC(arom.)); 7.17–7.13 (m, 2H, HC(arom.)); 4.36–4.27 (m, 
2H, H2C(alk.)); 4.05 (dd, 
2JH,H = 14.4, 
3JH,H = 4.8, 1H, H2C–N); 3.93 (dd, 
2JH,H = 14.4, 
3JH,H = 7.8, 1H, H2C–N); 3.57, 3.55 (AB, JAB = 13.2, 2H, H2C–Ph); 3.16–3.10 (m, 1H, 
H2C(5’), 1H, HC(2’)); 2.57–2.52 (m, 1H, H2C(5’)); 2.15 (s, 3H, H3C–C(4)); 2.08 (s, 
3H, H3C–C(5)); 2.07–2.01 (m, 1H, H2C(3’)); 1.86–1.80 (m, 1H, H2C(4’)); 1.78–1.71 
(m, 2H, H2C(alk.); 1H, H2C(4’)); 1.54–1.49 (m, 1H, H2C(3’)); 1.56–1.40 (m, 2H, 
H2C(alk.)); 1.35–1.24 (m, 8H, H2C(alk.)); 0.89 (t, JH,H = 7.2, 3H, H3C(alk.)). 
13C NMR 
(CDCl3): ´  139.4 (1 C(arom.)); 131.3 (HC(2)); 129.0, 128.5, 127.3, 124.8, 123.5 (5 
C(arom.), 2 C(imid.)); 62.4 (HC(2’)); 60.6 (CH2–Ph); 54.9 (C(5’)); 50.9 (CH2–N); 
29.4, 28.3 (2 C(alk.)); 28.0 (C(3’)); 25.7 (C(alk.)); 24.0 (C(4’)); 22.8 (C(alk.)); 14.3 
(H3C(alk.)); 8.7 (H3C–C(5)), 7.3 (H3C–C(4)). [±]D
25 = –26 (c = 1.0, CH2Cl2). 
 
4.2.9.3. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-3-butoxy-4-methyl-5-phenyl-1H-
imidazolium tetrafluoroborate 13c  
Yield: 1.6 g (70%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3584w, 3366m, 
3135m, 3061m, 2961m, 2874m, 2806m, 1679m, 1543m, 1496m, 1452m, 1380m, 
1283w, 1058m, 934m, 822w, 756m, 736m, 702s. 1H NMR (CDCl3): ´  9.08 (s, 1H, 
HC(2)); 7.53–7.48 (m, 3H, HC(arom.)); 7.28–7.13 (m, 7H, HC(arom.)); 4.52–4.43 (m, 
2H, H2C(alk.)); 4.04 (dd, 
2JH,H = 14.4, 
3JH,H = 4.8, 1H, H2C–N); 3.95 (dd, 
2JH,H = 14.4, 
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3JH,H = 7.8, 1H, H2C–N); 3.57, 3.45 (AB, JAB = 12.6, 2H, H2C–Ph); 3.06–3.02 (m, 1H, 
H2C(5’)); 2.91–2.86 (m, 1H, HC(2’)); 2.52–2.47 (m, 1H, H2C(5’)); 2.16 (s, 3H, H3C–
C(4)); 1.86–1.79 (m, 2H, H2C(alk.), 1H, H2C(3’)); 1.78–1.71 (m, 1H, H2C(4’)); 1.63–
1.50 (m, 2H, H2C(alk.); 1H, H2C(4’)); 1.43–1.28 (m, 1H, H2C(3’)); 1.00 (t, JH,H = 7.2, 
3H, H3C(alk.)). 
13C NMR (CDCl3): ´  139.3 (1 C(arom.)); 132.1 (HC(2)); 130.9, 130.8, 
129.7, 129.1, 129.0, 128.5, 127.3, 124.9, 124.8 (10 HC(arom.); 1 C(arom.), 2 C(imid.));  
83.2 (C(alk.)); 62.3 (HC(2’)); 60.1 (CH2–Ph); 54.4 (C(5’)); 50.6 (CH2–N); 30.1 
(C(alk.)); 27.9 (C(4’)); 23.8 (C(3’)); 19.1, 13.9 (2 C(alk.)); 7.5 (H3C–C(4)). [±]D
25 = –
25 (c = 1.0, CH2Cl2). 
 
4.2.9.4. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-3-hexyloxy-4-methyl-5-phenyl-
1H-imidazolium tetrafluoroborane 13d  
Yield: 1.9 g (76%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3584w, 3369m, 
3135m, 3061m, 2930m, 2872m, 2807m, 1683m, 1542m, 1496m, 1453m, 1379m, 
1283w, 1058m, 933m, 913m, 765m, 735m, 702s. 1H NMR (CDCl3): ´  9.10 (s, 1H, 
HC(2)); 7.55–7.48 (m, 3H, HC(arom.)); 7.29–7.14 (m, 7H, HC(arom.)); 4.51–4.42 (m, 
2H, H2C(alk.)); 4.04 (dd, 
2JH,H = 14.0, 
3JH,H = 4.8, 1H, H2C–N); 3.95 (dd, 
2JH,H = 14.0, 
3JH,H = 7.8, 1H, H2C–N); 3.57, 3.45 (AB, JAB = 13.2, 2H, H2C–Ph); 3.06–3.02 (m, 1H, 
H2C(5’)); 2.92–2.87 (m, 1H, HC(2’)); 2.53–2.47 (m, 1H, H2C(5’)); 2.16 (s, 3H, H3C–
C(4)); 1.87–1.80 (m, 2H, H2C(alk.); 1H, H2C(3’)); 1.78–1.71 (m, 1H, H2C(4’)); 1.64–
1.57 (m, 1H, H2C(4’)); 1.51–1.46 (m, 2H, H2C(alk.)); 1.37–1.28 (m, 4H, H2C(alk.), 1H, 
H2C(3’)); 0.92 (t, JH,H = 6.9, 3H, H3C(alk.)). 
13C NMR (CDCl3): ´  139.3 (1 C(arom.)); 
132.1 (HC(2)); 131.0, 130.9, 129.6, 129.1, 129.0, 128.5, 127.3, 124.9, 124.8 (10 
HC(arom.); 1 C(arom.), 2 C(imid.)); 83.5 (C(alk.)); 62.3 (HC(2’)); 60.1 (CH2–Ph); 54.4 
(C(5’)); 50.6 (CH2–N); 31.6, 28.1 (2 C(alk.)); 27.9 (C(3’)); 25.4 (C(alk.)); 23.8 (C(4’)); 
22.7 (C(alk.)); 14.2 (H3C(alk.)); 7.6 (H3C–C(4)). [±]D
25 = –17 (c = 1.0, CH2Cl2). 
 
4.2.9.5. 1-{[(2S)-N-Benzylpyrrolidin-2-yl]methyl}-3-butoxy-4,5-diphenyl-1H-
imidazolium tetrafluoroborate 13e  
Yield: 1.5 g (53%). Pale yellow oil (Al2O3, CHCl3). IR (film): v 3648w, 3584w, 
3369w, 3135m, 3061m, 2961m, 2874m, 2808m, 1683m, 1494m, 1447m, 1271m, 
1179m, 1058m, 934m, 819m, 763m, 735m, 700m, 607w. 1H NMR (CDCl3): ´  9.24 (s, 
1H, HC(2)); 7.50–7.20 (m, 15H, HC(arom.)); 4.26–4.19 (m, 1H, H2C–N, 2H, 
H2C(alk.)); 4.10 (dd, 
2JH,H = 13.8, 
3JH,H = 7.2, 1H, H2C–N); 3.65, 3.49 (AB, JAB = 13.2, 
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2H, H2C–Ph); 3.06–3.01 (m, 1H, H2C(5’)); 2.98–2.92 (m, 1H, HC(2’)); 2.53–2.47 (m, 
1H, H2C(5’)); 1.89–1.82 (m, 1H, H2C(3’)); 1.79–1.73 (m, 1H, H2C(4’)); 1.64–1.56 (m, 
2H, H2C(alk.); 1H, H2C(4’)); 1.36–1.32 (m, 1H, H2C(3’)); 1.31–1.24 (m, 2H, 
H2C(alk.)); 0.79 (t, JH,H = 7.5, 3H, H3C(alk.)). 
13C NMR (CDCl3): ´  139.3 (1 C(arom.)); 
133.1 (HC(2)); 131.3, 130.9, 130.4, 129.8, 129.73, 129.68, 129.2, 129.1, 128.7, 127.6, 
126.8, 124.6, 123.4 (15 HC(arom.), 2 C(arom.) 2 C(imid.)); 83.4 (C(alk.)); 62.3 
(C(2’)); 59.8 (CH2–Ph); 54.1 (C(5’)); 50.4 (CH2–N); 29.8 (C(alk.)); 23.6 (C(3’)); 18.8 
(C(4’)); 13.7 (H3C(alk.)). [±]D
25 = –16 (c = 1.0, CH2Cl2). 
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